China's 2021 NDRL listing sees price cuts of up to 95%
By Wang Fangqing
The updated Chinese national drug reimbursement list, released on December 3 by the National Healthcare security Administration (NHSA), showed clearly that China wants more affordable rare disease drugs and innovative cancer drugs, reports The Pharma Letter’s local correspondent.
The 2021 National Reimbursement Drug List (NDRL), effective on January 1, 2022, covers 2,860 drugs, slightly more than 2020’s 2,800. Price negotiations initially targeted 117 drugs, but eventually 94 drugs, including 67 new drugs and 27 drugs that were already covered by the 2020 NDRL, made the cut. The average price cuts among the 67 drugs were 61.7%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze